These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 15607374)

  • 21. Listeria monocytogenes meningitis following imatinib mesylate-induced monocytopenia in a patient with chronic myeloid leukemia.
    Ferrand H; Tamburini J; Mouly S; Bouscary D; Bergmann JF
    Clin Infect Dis; 2005 Dec; 41(11):1684-5. PubMed ID: 16267747
    [No Abstract]   [Full Text] [Related]  

  • 22. Heliotrope-like eruption mimicking dermatomyositis in a patient treated with imatinib mesylate for chronic myeloid leukemia.
    Kuwano Y; Asahina A; Watanabe R; Fujimoto M; Ihn H; Tamaki K
    Int J Dermatol; 2006 Oct; 45(10):1249-51. PubMed ID: 17040457
    [No Abstract]   [Full Text] [Related]  

  • 23. Vitiligo-like lesions in an adult patient treated with Imatinib mesylate.
    Cerchione C; Fabbricini R; Pane F; Luciano L
    Leuk Res; 2009 Aug; 33(8):e104-5. PubMed ID: 19232719
    [No Abstract]   [Full Text] [Related]  

  • 24. Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.
    François H; Coppo P; Hayman JP; Fouqueray B; Mougenot B; Ronco P
    Am J Kidney Dis; 2008 Feb; 51(2):298-301. PubMed ID: 18215707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extramedullary blast crises in CML patients in complete hematological remission treated with imatinib mesylate.
    Simpson E; O'Brien SG; Reilly JT
    Clin Lab Haematol; 2006 Jun; 28(3):215-6. PubMed ID: 16706941
    [No Abstract]   [Full Text] [Related]  

  • 26. Imatinib-associated hyperpigmentation, a side effect that should be recognized.
    Mcpherson T; Sherman V; Turner R
    J Eur Acad Dermatol Venereol; 2009 Jan; 23(1):82-3. PubMed ID: 18384557
    [No Abstract]   [Full Text] [Related]  

  • 27. [Psoriasis vulgaris exacerbated by imatinib therapy in chronic myelogenous leukemia].
    Shimizu K; Kuroda H; Kida M; Watanabe H; Shirao S; Akiyama T; Fujimi A; Tanaka I; Sato T; Matsunaga T; Niitsu Y
    Rinsho Ketsueki; 2005 Oct; 46(10):1152-5. PubMed ID: 16440780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Adverse effects of imatinib mesylate].
    Isshiki I
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():404-7. PubMed ID: 17474438
    [No Abstract]   [Full Text] [Related]  

  • 29. Imatinib mesylate-induced neutrophilic folliculitis in a teenager.
    García-Romero MT; Durán-McKinster C; de Ocariz MS; Carrasco-Daza D; Palacios-López C; Orozco-Covarrubias L; Ruiz-Maldonado R
    Int J Dermatol; 2012 Dec; 51(12):1529-30. PubMed ID: 22486540
    [No Abstract]   [Full Text] [Related]  

  • 30. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
    J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. STI-571 (Gleevec) in the treatment of chronic myeloid leukaemia.
    Kumar L; Kumari M; Menon H
    Natl Med J India; 2002; 15(5):298. PubMed ID: 12502149
    [No Abstract]   [Full Text] [Related]  

  • 32. Follicular acneiform eruption induced by imatinib.
    Martín JM; Jordá E; Monteagudo C; Alonso V; García L; Villalón G
    J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1368-70. PubMed ID: 17062082
    [No Abstract]   [Full Text] [Related]  

  • 33. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
    Gambacorti-Passerini C; Tornaghi L; Franceschino A; Piazza R; Corneo G; Pogliani E
    Nat Med; 2007 Jan; 13(1):13-4; author reply 15-6. PubMed ID: 17206117
    [No Abstract]   [Full Text] [Related]  

  • 34. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
    Hatfield A; Owen S; Pilot PR
    Nat Med; 2007 Jan; 13(1):13; author reply 15-6. PubMed ID: 17206118
    [No Abstract]   [Full Text] [Related]  

  • 35. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
    Rosti G; Martinelli G; Baccarani M
    Nat Med; 2007 Jan; 13(1):15; author reply 15-6. PubMed ID: 17206121
    [No Abstract]   [Full Text] [Related]  

  • 36. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
    Atallah E; Kantarjian H; Cortes J
    Nat Med; 2007 Jan; 13(1):14; author reply 15-6. PubMed ID: 17206119
    [No Abstract]   [Full Text] [Related]  

  • 37. Imatinib mesylate induced erythroderma.
    Sanghavi SA; Dongre AM; Khopkar US
    Indian J Dermatol Venereol Leprol; 2012; 78(3):408. PubMed ID: 22565463
    [No Abstract]   [Full Text] [Related]  

  • 38. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.
    Pawarode A; Sait SN; Nganga A; Coignet LJ; Barcos M; Baer MR
    Leuk Res; 2007 Nov; 31(11):1589-92. PubMed ID: 17391756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjunctive chromosomal abnormalities in Philadelphia-negative cells of CML patients treated with Imatinib.
    Cervetti G; Galimberti S; Fazzi R; Papineschi F; Azzarà A; Simi P; Petrini M
    Eur J Clin Invest; 2004 Mar; 34(3):243-4. PubMed ID: 15025685
    [No Abstract]   [Full Text] [Related]  

  • 40. Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib.
    Franceschino A; Tornaghi L; Benemacher V; Assouline S; Gambacorti-Passerini C
    Haematologica; 2008 Feb; 93(2):317-8. PubMed ID: 18245661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.